Eyenovia (EYEN) is planning to raise $30 million in an initial public offering (IPO) on the week of January 22nd, IPO Scoop reports. The company plans to issue 2,700,000 shares at a price of $10.00-$12.00 per share.
Eyenovia has a market-cap of $109.3 million.
Ladenburg Thalmann and Roth Capital Partners acted as the underwriters for the IPO.
Eyenovia provided the following description of their company for its IPO: ” We are a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing our patented piezo-print technology to deliver micro-therapeutics topically to the eye. This micro-dosing technology has the potential to replace traditional macro-dosing applications (e.g. conventional eye droppers that deliver 30–50 µL) that routinely overdose or under-dose when used in the topical administration of ophthalmic therapeutics. “.
Eyenovia was founded in 2014 and has 7 employees. The company is located at 501 Fifth Avenue, Suite 1404, New York, NY 10017, US and can be reached via phone at 917-289-1117. or on the web at http://www.eyenovialab.com.
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.